Innate Pharma Q2 Earnings Call Highlights

Key Points

• Innate Pharma strengthened its finances through a Sobi partnership for lacutamab, including a $75 million upfront payment, and a €30 million equity financing. The company expects its cash runway to extend through the end of Q1 2028.
• Lacutamab’s phase III TELLOMAK-3 trial has begun, with enrollment expected in Q1 2027 and a potential accelerated-approval filing for Sézary syndrome planned for the second half of 2027. Sobi holds potential global commercialization and development rights under the agreement.
• The company expects key clinical updates in the second half of 2026, including a PACIFIC-9 phase III readout for monalizumab and initial phase I data for IPH4502, an antibody-drug conjugate that has shown preliminary responses in several heavily pretreated solid-tumor populations.

Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.

Chief Executive Officer Jonathan Dickinson said the Sobi transaction became effective following its closing and included a $75 million upfront payment. Combined with a €30 million equity financing, the company expects the funding to extend its projected cash runway through the end of the first quarter of 2028.

Lacutamab Partnership and Regulatory Plans

Lacutamab, Innate’s anti-KIR3DL2 antibody, is being developed for cutaneous T-cell lymphoma. The company said it has initiated the TELLOMAK-3 confirmatory phase III trial, with the first patient expected to be enrolled in the first quarter of 2027.

The study includes a confirmatory cohort in Sézary syndrome and a registrational cohort in mycosis fungoides, according to Chief Medical Officer Markus Jensen. Innate plans to seek accelerated approval in Sézary syndrome in the second half of 2027 based on existing phase II TELLOMAK data once the phase III study is underway.

Jensen said lacutamab has received FDA Breakthrough Therapy designation for relapsed or refractory Sézary syndrome, as well as FDA Fast Track designation, European Medicines Agency PRIME designation, and orphan-drug designations in the U.S. and Europe.

Under the Sobi agreement, Innate will conduct the phase III trial and file for potential accelerated approval. If the product receives accelerated approval, Sobi would receive exclusive global commercialization rights. Following positive phase III results, Sobi could obtain full global development rights.

• $75 million upfront payment
• Up to $40 million in near-term Sézary syndrome milestones
• Up to an additional $465 million tied to development-rights options and future regulatory and commercial milestones
• Tiered double-digit royalties on future net sales

During the question-and-answer session, Dickinson said the company expects lacutamab could be included in National Comprehensive Cancer Network guidelines after a potential accelerated approval. He said Innate expects physicians may use the treatment off-label in earlier lines of therapy and in mycosis fungoides, though the initial accelerated approval filing would be for Sézary syndrome.

Dickinson also said pricing research conducted with U.S. payers indicated potential annual pricing of between €500,000 and €625,000 per patient, supported by the company’s clinical data and a potential NCCN listing.

IPH4502 Data Presentation Ahead

Innate completed phase I dose escalation and cohort-enrichment enrollment for IPH4502, its Nectin-4 exatecan antibody-drug conjugate for advanced solid tumors. The company reported preliminary antitumor activity, including objective responses in heavily pretreated patients with urothelial cancer after prior enfortumab vedotin treatment, as well as in non-small cell lung cancer and head and neck cancer.

The company said it has observed a favorable safety profile to date, including limited hematological toxicity. Jensen said approximately 15 patients have been enrolled in each of the post-enfortumab vedotin urothelial cancer and head and neck cancer cohorts, while enrollment in the non-small cell lung cancer cohort was lower.

Management attributed the observed safety profile in part to the molecule’s stable proprietary linker, which it said may limit the release of free payload associated with systemic toxicity in some antibody-drug conjugates.

Innate plans to present initial phase I dose-escalation data at the EORTC-NCI-AACR meeting in Barcelona in November. Management referenced November 18 during prepared remarks, while Jensen referenced November 26 during his presentation.

Jensen said the dataset spans 11 indications and 76 patients and is expected to provide both safety and response information to guide next development steps. Dickinson said the recent equity financing should allow Innate to move into dose optimization, while expansion into multiple additional tumor types could require further funding.

Monalizumab Readout Expected in Second Half

Enrollment has been completed in PACIFIC-9, a randomized phase III trial of monalizumab in unresectable stage III non-small cell lung cancer. The study enrolled 1,051 patients who had not progressed following definitive platinum-based concurrent chemoradiotherapy.

PACIFIC-9 compares durvalumab plus oleclumab, durvalumab plus monalizumab, and durvalumab plus placebo, with progression-free survival as the primary endpoint. Innate continues to expect a phase III readout during the second half of 2026.

Chief Operating Officer Yannis Morel said Innate has received €450 million to date under its monalizumab partnership with AstraZeneca. The agreement also includes up to €825 million in additional potential milestones, double-digit royalties outside Europe, and 50% profit sharing in Europe.

Financial Position

Chief Financial Officer Frédéric Lombard said Innate had €21.4 million in cash equivalents and financial assets as of June 30, 2026. That balance excluded the Sobi upfront payment, which the company valued at approximately €65 million, and proceeds from the equity offering.

The €30 million offering is expected to generate approximately €28 million in net proceeds. Innate said the funds are intended to support continued IPH4502 clinical development, advancement of its preclinical antibody-drug conjugate portfolio, and general corporate purposes.

About Innate Pharma (NASDAQ:IPHA)

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma's pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.